News headlines about Mylan (NASDAQ:MYL) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Mylan earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.6205195680911 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media stories that may have effected Accern’s analysis:
- 3 Top Healthcare Stocks to Buy in February – nwitimes.com (nwitimes.com)
- Here’s What Teva Pharmaceutical’s Saying About Its Future (fool.com)
- Here's What Teva Pharmaceutical's Saying About Its Future (finance.yahoo.com)
- Mylan (MYL) Sees Significant Decrease in Short Interest (americanbankingnews.com)
A number of equities research analysts recently issued reports on MYL shares. Zacks Investment Research cut shares of Mylan from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. BidaskClub upgraded shares of Mylan from a “hold” rating to a “buy” rating in a research report on Friday, October 27th. Leerink Swann initiated coverage on shares of Mylan in a research report on Tuesday, January 2nd. They issued a “market perform” rating and a $44.00 price objective for the company. Mizuho restated a “buy” rating and issued a $37.00 price objective on shares of Mylan in a research report on Tuesday, October 24th. Finally, Cantor Fitzgerald set a $34.00 price objective on shares of Mylan and gave the company a “hold” rating in a research report on Tuesday, October 31st. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $44.65.
Mylan (NASDAQ MYL) traded up $0.03 during trading on Friday, reaching $39.28. 6,785,732 shares of the company traded hands, compared to its average volume of 5,613,673. Mylan has a twelve month low of $29.39 and a twelve month high of $47.82. The company has a market cap of $21,071.21, a price-to-earnings ratio of 24.40, a price-to-earnings-growth ratio of 1.06 and a beta of 1.35. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05.
In related news, CEO Heather M. Bresch sold 75,000 shares of Mylan stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $3,375,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.69% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Mylan (MYL) Earns Media Impact Rating of 0.14” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/02/11/mylan-myl-receiving-somewhat-favorable-media-coverage-analysis-finds.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.